HC Wainwright Has Positive Estimate for OKUR Q2 Earnings

OnKure Therapeutics, Inc. (NASDAQ:OKUR) – Equities research analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for shares of OnKure Therapeutics in a note issued to investors on Monday, July 20th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.39) per share for the quarter, up from their previous forecast of ($0.93). HC Wainwright has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($3.19) per share. HC Wainwright also issued estimates for OnKure Therapeutics’ Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.44) EPS and FY2026 earnings at ($1.94) EPS.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.37).

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings upgraded shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. JonesTrading cut shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Finally, Wall Street Zen raised shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $21.00.

OnKure Therapeutics Trading Up 1.2%

Shares of NASDAQ OKUR opened at $4.17 on Wednesday. The firm has a market capitalization of $168.45 million, a price-to-earnings ratio of -0.96 and a beta of 0.27. OnKure Therapeutics has a one year low of $1.91 and a one year high of $5.38. The business has a fifty day simple moving average of $4.17 and a 200 day simple moving average of $3.74.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. ADAR1 Capital Management LLC boosted its stake in shares of OnKure Therapeutics by 140.1% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,434,941 shares of the company’s stock valued at $10,081,000 after purchasing an additional 1,420,783 shares in the last quarter. Vivo Capital LLC acquired a new stake in shares of OnKure Therapeutics during the 1st quarter worth about $7,981,000. Shay Capital LLC increased its position in shares of OnKure Therapeutics by 17.4% during the 3rd quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock worth $2,524,000 after purchasing an additional 135,888 shares in the last quarter. Prosight Management LP lifted its holdings in OnKure Therapeutics by 204.9% during the 4th quarter. Prosight Management LP now owns 816,909 shares of the company’s stock valued at $2,369,000 after purchasing an additional 548,950 shares during the last quarter. Finally, Rosalind Advisors Inc. bought a new position in OnKure Therapeutics during the 4th quarter valued at about $2,118,000. 90.98% of the stock is owned by institutional investors.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.